Francois et al. showed that patients with systemic sclerosis (a CTD) and higher serum BAFF levels had a significantly higher incidence of pulmonary fibrosis and thus determined that BAFF was a potential therapeutic target [48]. The gene discussed is TNFSF13B; the disease is pulmonary fibrosis.